Brownlie Keith L 4

What Happened Keith L. Brownlie, a director of Celldex Therapeutics (CLDX), was granted a derivative award of 26,000 shares on 2026-06-25. The Form 4 reports the award as 26,000 shares @ $0.00 (derivative), indicating an option grant rather than a cash purchase or exercise. The filing footnote states the option was granted under Celldex's 2021 Omnibus Equity Incentive Plan. The grant itself does not show an immediate cash value or exercise action.

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within the standard 2 business-day window).
• Reported transaction: Award/Grant (code A) of 26,000 derivative shares @ $0.00.
• Footnote: Option granted pursuant to the 2021 Omnibus Equity Incentive Plan (F1).
• Shares owned following the transaction: not specified in this filing.
• No exercise, sale, or tax-withholding reported in this Form 4.

Context This was an option grant (a compensation award) — not an exercise or cash purchase. Option grants to directors are common as part of compensation and do not by themselves indicate buying or selling sentiment. The filing does not disclose strike price, vesting schedule, or other grant terms, so consult company proxy statements or subsequent filings for those details.